Sara Tinsley, PhD, APRN, AOCN, on CLL: Minimal Residual Disease After Venetoclax and Rituximab Therapy

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to know about the findings of the MURANO study, which analyzed patients with relapsed or refractory chronic lymphocytic leukemia who had enduring undetectable minimal residual disease after receiving fixed-duration treatment with venetoclax and rituximab (Abstract 125).